

Juan Carlos Garcia-Ruiz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8111616/publications.pdf>

Version: 2024-02-01

42
papers

1,596
citations

331670

21
h-index

302126

39
g-index

44
all docs

44
docs citations

44
times ranked

2146
citing authors

#	ARTICLE	IF	CITATIONS
1	Alveolar rhabdomyosarcoma with cannibalism and erythroid leukaemia-like morphology. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 1007-1008.	1.3	0
2	Systematic review of the potential of MicroRNAs in the management of patients with follicular lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103247.	4.4	6
3	Acute megakaryoblastic leukaemia with erythrophagocytosis. <i>British Journal of Haematology</i> , 2021, 194, 658-658.	2.5	1
4	Lymphocytes with auer rod-like inclusions in chronic lymphocytic leukemia. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, , .	0.2	0
5	Biomarkers for the diagnosis of invasive candidiasis in immunocompetent and immunocompromised patients. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115509.	1.8	13
6	The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers. <i>Cancers</i> , 2021, 13, 5418.	3.7	7
7	Hairy kidney in high-grade B-cell lymphoma. <i>International Journal of Hematology</i> , 2021, 115, 3.	1.6	0
8	Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 7-15.	4.4	19
9	Sequencing of <i>FKS</i> Hot Spot 1 from <i>Saprochaete capitata</i> To Search for a Relationship to Reduced Echinocandin Susceptibility. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	7
10	Molecular Identification of <i>Saprochaete capitata</i> in Human Blood and Paraffinized Tissue Samples. <i>Journal of Clinical Microbiology</i> , 2017, 55, 2556-2559.	3.9	1
11	Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO). <i>Annals of Hematology</i> , 2017, 96, 1323-1330.	1.8	5
12	The hypoxia signalling pathway in haematological malignancies. <i>Oncotarget</i> , 2017, 8, 36832-36844.	1.8	37
13	Severe neonatal jaundice due to a <i>de novo</i> glucose-6-phosphate dehydrogenase deficient mutation. <i>International Journal of Laboratory Hematology</i> , 2016, 38, e27-9.	1.3	3
14	Hereditary xerocytosis, a misleading anemia. <i>Annals of Hematology</i> , 2016, 95, 1545-1546.	1.8	13
15	Detection of new pathogenic mutations in patients with congenital haemolytic anaemia using next-generation sequencing. <i>International Journal of Laboratory Hematology</i> , 2016, 38, 629-638.	1.3	36
16	Disseminated fusariosis and hematologic malignancies, a still devastating association. Report of three new cases. <i>Revista Iberoamericana De Micología</i> , 2015, 32, 190-196.	0.9	11
17	Myeloid sarcoma preceding an acute promyelocytic leukaemia with neuromeningeal infiltration. <i>Annals of Hematology</i> , 2014, 93, 339-340.	1.8	11
18	Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma: A Retrospective Study of the Geltamo Group (1994-2011). <i>Blood</i> , 2014, 124, 3980-3980.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Invasive infections caused by <i>Saprochaete capitata</i> in patients with haematological malignancies: Report of five cases and review of the antifungal therapy. <i>Revista Iberoamericana De Micologia</i> , 2013, 30, 248-255.	0.9	58
20	Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. <i>Haematologica</i> , 2012, 97, 616-621.	3.5	19
21	Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. <i>Blood</i> , 2011, 118, 529-534.	1.4	183
22	Primary Bone Lymphoma. <i>Journal of Clinical Rheumatology</i> , 2010, 16, 392-394.	0.9	0
23	Busulfan 12 mg/kg plus melphalan 140 mg/m ² versus melphalan 200 mg/m ² as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. <i>Haematologica</i> , 2010, 95, 1913-1920.	3.5	101
24	The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. <i>Blood</i> , 2009, 114, 4369-4372.	1.4	67
25	Primary mediastinal large cell lymphoma (PMBL): frontline treatment with autologous stem cell transplantation (ASCT). The GEL-TAMO experience. <i>Hematological Oncology</i> , 2008, 26, 171-178.	1.7	30
26	Contribution of serum biomarkers to the diagnosis of invasive candidiasis. <i>Expert Review of Molecular Diagnostics</i> , 2008, 8, 315-325.	3.1	14
27	Evaluation of a Novel Enzyme-Linked Immunosorbent Assay To Detect Immunoglobulin G Antibody to Enolase for Serodiagnosis of Invasive Candidiasis. <i>Vaccine Journal</i> , 2007, 14, 318-319.	3.1	33
28	Diagnosis of invasive candidiasis by enzyme-linked immunosorbent assay using the N-terminal fragment of <i>Candida albicans</i> hyphal wall protein 1. <i>BMC Microbiology</i> , 2007, 7, 35.	3.3	39
29	Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. The GEL-TAMO experience. <i>European Journal of Haematology</i> , 2007, 78, 290-296.	2.2	59
30	Front-Line Autologous Stem Cell Transplantation (ASCT) in Primary Mediastinal Large B-Cell Lymphoma: The GEL-TAMO Experience.. <i>Blood</i> , 2006, 108, 3056-3056.	1.4	2
31	Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. <i>Annals of Oncology</i> , 2005, 16, 625-633.	1.2	198
32	Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience. <i>Annals of Oncology</i> , 2004, 15, 1504-1509.	1.2	41
33	Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Español de Síndromes Linfoproliferativos/Trasplante Autólogo de Médula "sea phase II trial. <i>British Journal of Haematology</i> , 2003, 120, 296-303.	2.5	31
34	High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. <i>Annals of Oncology</i> , 2003, 14, 140-151.	1.2	63
35	Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome. <i>Annals of Oncology</i> , 2003, 14, 745-751.	1.2	40
36	Myeloablative Treatments for Multiple Myeloma: Update of a Comparative Study of Different Regimens Used in Patients from the Spanish Registry for Transplantation in Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 2002, 43, 67-75.	1.3	45

#	ARTICLE	IF	CITATIONS
37	Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Bone Marrow Transplantation, 2001, 27, 405-412.	2.4	70
38	Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. British Journal of Haematology, 2000, 109, 138-147.	2.5	69
39	Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. British Journal of Haematology, 2000, 109, 438-446.	2.5	100
40	Are myeloma patients with renal failure candidates for autologous stem cell transplantation?. The Hematology Journal, 2000, 1, 28-36.	1.4	104
41	Cholangitis Due to Aspergillus fumigatus in a Patient with Acute Leukemia. Clinical Infectious Diseases, 1998, 26, 228-229.	5.8	7
42	Continuous hemofiltration in the management of "retinoic acid syndrome". Leukemia Research, 1997, 21, 891.	0.8	1